Use of Buprenorphine in treatment of refractory depression—A review of current literature-Reference-Cited by-同舟云学术

Use of Buprenorphine in treatment of refractory depression—A review of current literature

Published:2017-04 Issue: Volume:26 Page:94-98
ISSN:1876-2018
Container-title:Asian Journal of Psychiatry
language:en
Short-container-title:Asian Journal of Psychiatry

Author:

Stanciu Cornel N.,Glass Oliver M.,Penders Thomas M.

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,General Psychology,General Medicine

Reference42 articles.

1. Practice Guideline for the Treatment of Patients with Major Depressive Disorder;American Psychiatric Association,2010

2. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats;Bals-Kubik;J. Pharmacol. Exp. Ther.,1993

3. Opiates as antidepressants;Berrocoso;Curr. Pharm. Des.,2009

4. Buprenorphine treatment of refractory depression;Bodkin;J. Clin. Psychopharmacol.,1995

5. Cross-national epidemiology of DSM-IV major depressive episode;Bromet;BMC Med.,2011

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Buprenorphine-Associated Behavioral and Psychotic Side Effects;Journal of Clinical Psychopharmacology;2024-08-28

2. Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder;Expert Opinion on Emerging Drugs;2024-05-08

3. Suicide within 1 year of non-fatal overdose: Risk factors and risk reduction with medications for opioid use disorder;General Hospital Psychiatry;2024-01

4. Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment;Alcohol: Clinical and Experimental Research;2023-08-30

5. The differential influence of PZM21, a nonrewarding μ-opioid receptor agonist with G protein bias, on behavioural despair and fear response in mice;Behavioural Brain Research;2023-07